Latest Ratios: P/E Ratio 1.0x · EV/EBITDA N/A · ROE N/A. (1999–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $538M | $421M | $395M | $408M | $562M | $1.7B | $866M | $330M | $318M | $476M | $619M |
| Enterprise Value | $11.9B | $11.7B | $12.5B | $12.5B | $12.8B | $14.1B | $12.1B | $14.1B | $13.7B | $13.8B | $15.6B |
| P/E Ratio → | 1.01 | 0.83 | — | — | 12.34 | 7.56 | 1.70 | — | — | — | — |
| P/S Ratio | 0.04 | 0.03 | 0.03 | 0.03 | 0.05 | 0.14 | 0.07 | 0.02 | 0.02 | 0.03 | 0.03 |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | 0.27 |
| P/FCF | 2.59 | 2.02 | 3.29 | — | — | — | 0.50 | — | — | 2.35 | 0.42 |
| P/OCF | 0.99 | 0.78 | 0.82 | 1.94 | 1.87 | — | 0.40 | 0.86 | 1.16 | 0.62 | 0.26 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.94 | 0.99 | 1.00 | 1.05 | 1.14 | 1.02 | 1.07 | 0.97 | 0.90 | 0.85 |
| EV / EBITDA | — | — | 13.14 | 9.08 | 10.10 | 7.66 | 7.73 | 12.44 | 17.86 | — | 400.64 |
| EV / EBIT | — | 7.37 | 14.78 | 14.42 | 17.85 | 11.00 | 21.07 | 15.68 | 15.38 | 64.01 | 14.44 |
| EV / FCF | — | 56.45 | 103.83 | — | — | — | 6.95 | — | — | 68.11 | 10.49 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 8.7% | 8.7% | 41.7% | 40.7% | 40.2% | 41.1% | 37.5% | 38.7% | 38.3% | 34.6% | 36.9% |
| Operating Margin | -79.4% | -79.4% | 4.3% | 7.7% | 6.7% | 11.3% | 9.6% | 4.9% | 1.5% | -12.2% | -4.7% |
| Net Profit Margin | 4.1% | 4.1% | -4.1% | -1.1% | 0.4% | 1.9% | 4.3% | -4.5% | -5.6% | -16.0% | -9.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | -232.3% | -49.5% |
| ROA | 3.7% | 3.7% | -3.6% | -0.9% | 0.3% | 1.5% | 3.2% | -3.7% | -4.7% | -12.5% | -7.1% |
| ROIC | -70.1% | -70.1% | 3.7% | 6.3% | 5.3% | 9.7% | 7.6% | 4.0% | 1.2% | -9.2% | -3.3% |
| ROCE | -87.3% | -87.3% | 4.5% | 7.7% | 6.5% | 10.8% | 8.5% | 4.9% | 1.5% | -11.0% | -4.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | 6.68 |
| Debt / EBITDA | — | — | 12.77 | 8.81 | 9.75 | 6.99 | 8.25 | 12.34 | 17.70 | — | 390.87 |
| Net Debt / Equity | — | — | — | — | — | — | — | — | — | — | 6.58 |
| Net Debt / EBITDA | — | — | 12.73 | 8.78 | 9.66 | 6.71 | 7.18 | 12.15 | 17.45 | — | 384.77 |
| Debt / FCF | — | 54.42 | 100.54 | — | — | — | 6.45 | — | — | 65.76 | 10.08 |
| Interest Coverage | 1.83 | 1.83 | 0.98 | 1.05 | 0.84 | 1.44 | 0.56 | 0.87 | 0.91 | 0.23 | 1.12 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.46 | 1.46 | 1.41 | 1.50 | 1.41 | 1.47 | 1.60 | 1.50 | 1.48 | 1.73 | 1.62 |
| Quick Ratio | 1.32 | 1.32 | 1.27 | 1.34 | 1.25 | 1.32 | 1.48 | 1.35 | 1.32 | 1.54 | 1.45 |
| Cash Ratio | 0.12 | 0.12 | 0.02 | 0.02 | 0.05 | 0.21 | 0.60 | 0.09 | 0.08 | 0.24 | 0.08 |
| Asset Turnover | — | 0.95 | 0.90 | 0.86 | 0.83 | 0.81 | 0.74 | 0.85 | 0.89 | 0.88 | 0.84 |
| Inventory Turnover | 35.41 | 35.41 | 22.25 | 22.59 | 20.69 | 20.52 | 22.01 | 22.88 | 21.74 | 22.63 | 24.24 |
| Days Sales Outstanding | — | 66.01 | 70.69 | 69.00 | 63.88 | 64.22 | 63.87 | 66.18 | 64.65 | 60.31 | 66.55 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 98.7% | 120.8% | — | — | 8.1% | 13.2% | 59.0% | — | — | — | — |
| FCF Yield | 38.6% | 49.4% | 30.4% | — | — | — | 200.7% | — | — | 42.6% | 240.6% |
| Buyback Yield | 0.4% | 0.5% | 0.3% | 1.0% | 1.4% | 0.3% | 0.1% | 0.3% | 0.3% | 1.1% | 1.0% |
| Total Shareholder Yield | 0.4% | 0.5% | 0.3% | 1.0% | 1.4% | 0.3% | 0.1% | 0.3% | 0.3% | 1.1% | 1.0% |
| Shares Outstanding | — | $135M | $132M | $130M | $130M | $131M | $117M | $114M | $113M | $112M | $111M |
High leverage and refinancing
According to current market data, CYH trades at a P/S ratio of 0.04 and a P/FCF of 2.22, suggesting that investors are pricing the equity for a potential restructuring rather than growth, a significant discount compared to the broader healthcare facility peer group's valuation multiples.
The extremely low P/S multiple indicates that the market assigns minimal value to the company's revenue stream, likely due to the high debt burden and persistent operational losses. This valuation profile suggests that the market is focused on the company's survival and debt-servicing capacity rather than its long-term earnings potential.
As reported in recent financial statements, CYH's ROIC has exhibited extreme volatility, swinging from a negative 79.6% in 2025Q4 to 26.1% in 2026Q1, which indicates that non-cash impairment charges are severely distorting the company's ability to generate meaningful returns on its invested capital base.
The erratic nature of these returns makes it difficult to assess the underlying efficiency of the hospital network. Investors should monitor whether the company can achieve consistent, positive ROIC once the portfolio rationalization process concludes and the asset base stabilizes.
Based on quarterly filings, the company's cash conversion cycle has shown significant instability, with DSO reaching 71 days in 2025Q3, reflecting ongoing challenges in collecting receivables and managing the timing of payments to suppliers within its fragmented rural hospital network.
The fluctuation in DSO and DPO suggests that the company lacks a stable working capital rhythm, which may be exacerbated by the divestiture of facilities and the resulting disruption in administrative processes. This inconsistency warrants further investigation into the company's ability to optimize its cash cycle under current operational constraints.
According to recent balance sheet disclosures, the current ratio has hovered around 1.47, yet the company's reliance on asset sales to maintain cash levels suggests that its liquidity position is highly sensitive to the timing and success of its ongoing divestiture program.
While the current ratio appears adequate on the surface, the lack of consistent operating cash flow means that the company is effectively living off the proceeds of its own liquidation. This reliance on non-recurring cash inflows creates a structural vulnerability that could be exposed by any delay in asset sales.
The P/E ratio is frequently misapplied to CYH, as the company's earnings are heavily impacted by non-recurring impairment charges and divestiture gains, which render traditional price-to-earnings metrics largely meaningless for assessing the underlying operational health of the business.
Investors should instead focus on EV/EBITDA or cash-flow-based metrics to evaluate the company's performance, as these provide a clearer view of the business's ability to generate cash before accounting for the massive non-cash charges that currently dominate the bottom line. Relying on P/E in this context risks misinterpreting accounting noise as fundamental value.
Includes 30+ ratios · 27 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CYH stock.
Community Health Systems, Inc.'s current P/E ratio is 1.0x. The historical average is 23.1x. This places it at the 5th percentile of its historical range.
Based on historical data, Community Health Systems, Inc. is trading at a P/E of 1.0x. This is at the 5th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Community Health Systems, Inc. has 8.7% gross margin and -79.4% operating margin.